Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)

被引：1
|
作者：
Hochster
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 28期
关键词：
D O I：
10.1200/JCO.2008.19.8630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4697 / 4697
页数：1
相关论文
共 50 条
  • [41] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
  • [42] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [43] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [44] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
  • [45] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
    Shaotang Li
    Pan Dr Chi
    BioDrugs, 2011, 25 : 43 - 50
  • [46] FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: Safety, efficacy and genetic polymorphisms
    Bécouarn Y.
    Cany L.
    Pulido M.
    Beyssac R.
    Texereau P.
    Le Morvan V.
    Béchade D.
    Brunet R.
    Aitouferoukh S.
    Lalet C.
    Mathoulin-Pélissier S.
    Fonck M.
    Robert J.
    BMC Research Notes, 7 (1)
  • [47] Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer
    Varol, Umut
    Oktay, Esin
    Yildirim, Mustafa
    Surmeli, Zeki Gokhan
    Dirican, Ahmet
    Meydan, Nezih
    Karaca, Burcak
    Karabulut, Bulent
    Uslu, Ruchan
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 166 - 170
  • [48] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
    Munoz, Alberto
    Pericay, Caries
    Garcia-Giron, Carlos
    Alonso, Vicente
    Duenas, Rosario
    Cirera, Luis
    Rivera, Fernando
    Falco, Esther
    Alvarez Bustos, Inaki
    Salud, Antonieta
    ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
  • [49] Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer
    Ravaioli, A
    Marangolo, M
    Pasquini, E
    Rossi, A
    Amadori, D
    Cruciani, G
    Tassinari, D
    Oliverio, G
    Giovanis, P
    Turci, D
    Zumaglini, F
    Nicolini, M
    Panzini, I
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2545 - 2550
  • [50] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
12345